Three technology appraisals (TAs) have been issued by NICE and four TAs have been updated, detailing evidence-based recommendations regarding whether the following drugs should be used for the specified indication:

TA357—Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab*

TA366—Pembrolizumab for advanced melanoma not previously treated with ipilimumab*

TA428—Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy*

TA439—Cetuximab*and panitumumabfor previously untreated metastatic colorectal cancer

TA474—Sorafenib for treating advanced hepatocellular carcinoma*

TA475—Dimethyl fumarate for treating moderate to severe plaque psoriasis

TA476—Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer

* only when the company provides the product in line with the commercial access agreement
†  only if the company provides the product with the discount agreed in the patient access scheme.

NICE TAs assess the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, as well as procedures, devices, and diagnostic agents. If the TA recommends a treatment as an option, the NHS must make sure it is available within 3 months (unless otherwise specified) of the TA publication date.